癌症生物標記市場規模、佔有率、成長分析，按分析技術、按癌症類型、按產品、按應用、按地區 - 行業預測，2024-2031 年

2022年，癌症生物標記的全球市場規模為238億美元，從2023年的264.7億美元成長到2031年的618.8億美元，預計在預測期內（2024-2031年）將成長。為11.8%。

全球癌症生物標記市場的預期成長與乳癌、攝護腺癌和肺癌等各種癌症盛行率的上升密切相關。這些癌症發生率的增加是未來幾年推動市場擴張的關鍵因素。此外，生物標的療法在癌症治療中的重要性日益增加，推動了對有效生物標記的需求。技術進步透過提高癌症生物標記的準確性和可靠性，最終提高診斷準確性和治療監測，在這一成長趨勢中發揮關鍵作用。這些技術創新將有助於改善患者預後並進一步加速市場成長。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 價格分析
• 專利分析
• 價值鏈分析
• 供應鏈分析
• 貿易分析
• 技術分析
• 客戶和購買標準分析
• 案例研究分析

癌症生物標記市場：依分析技術分類

• 市場概況
• 體學技術
  • 蛋白質體學
  • 免疫檢測
  • 質譜分析
  • 2D凝膠電泳
  • 蛋白質微陣列
  • 其他蛋白質體技術
  • 基因組學
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 原位雜合技術
  • 其他體學技術
• 成像技術
  • 超音波影像診斷
  • 電腦斷層掃描
  • 磁振造影
  • 正子斷層掃描
  • 乳房X光照相術

癌症生物標記市場：按癌症類型分類

• 非何傑金氏淋巴瘤
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌
• 惡性黑色素瘤
• 白血病
• 甲狀腺癌
• 膀胱癌
• 非何傑金氏淋巴瘤
• 腎癌
• 其他癌症

癌症生物標記市場：依產品

• 市場概況
• 裝置
  • 影像設備
  • 病理學設備
  • 切片檢查儀器
• 消耗品
  • 抗體
  • 試劑套件和試劑
  • 探測
• 生物資訊軟體

癌症生物標記市場：按應用分類

• 市場概況
• 診斷
• 研究與開發
• 預言
• 風險評估
• 其他用途

癌症生物標記市場：依最終用戶分類

• 市場概況
• 診斷實驗室
• 與生物製藥公司交叉
• 研究/學術機構
• 其他最終用戶

癌症生物標記市場：按地區分類的規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Thermo Fisher Scientific Inc.（US）
• Qiagen（Netherlands）
• Bio-Rad Laboratories, Inc.（US）
• Illumina, Inc.（US）
• Agilent Technologies, Inc.（US）
• Abbott Laboratories（US）
• bioMerieux（France）
• Merck KGaA（Germany）
• Becton, Dickinson and Company（US）
• Myriad Genetics, Inc.（US）
• Sysmex Corporation（Japan）
• Hologic, Inc.（US）
• Quest Diagnostics（US）
• Centogene NV（Germany）
• BioGenex（US）
• Siemens Healthineers（Germany）
• Exact Sciences（US）
• R&D Systems, Inc.（US, part of Bio-Techne）
• Biovision Inc.（US）
• Olink（Sweden）
• Meso Scale Diagnostics, LLC（US）
• Invivoscribe, Inc.（US）
• INOVIQ Ltd.（Australia）

Global Cancer Biomarkers Market size was valued at USD 23.8 billion in 2022 and is poised to grow from USD 26.47 billion in 2023 to USD 61.88 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The anticipated growth of the global cancer biomarkers market is closely tied to the rising prevalence of various cancer types, including breast, prostate, and lung cancers. The increasing incidence of these cancers is a key factor driving the market's expansion in the coming years. Moreover, the growing importance of biological and targeted therapies in cancer treatment is boosting the demand for effective biomarkers. Technological advancements play a critical role in this upward trend by improving the accuracy and reliability of cancer biomarkers, ultimately enhancing diagnostic precision and treatment monitoring. These innovations contribute to better patient outcomes, further accelerating the market's growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biomarkers Market Segmental Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technologies, Imaging Technologies. Based on Cancer Type, the market is segmented into Non-Hodgkin's Lymphoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer, and Other Cancers. Based on Product, the market is segmented into Instruments, Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Biomarkers Market

Many pharmaceutical companies are actively investing in cutting-edge research and development aimed at creating innovative biomarkers specifically designed for cancer diagnosis and treatment. Several of these biomarkers are approaching the final stages of development and are expected to make a substantial impact once introduced to the market. These upcoming biomarkers have the potential to transform cancer care by offering improved accuracy and effectiveness in both diagnosis and treatment. Their introduction could lead to more personalized approaches, significantly enhancing patient outcomes and setting new standards in the management of cancer.

Restraints in the Global Cancer Biomarkers Market

The increasing global incidence of cancer and the growing need for diagnostic tests highlight a major challenge in the cancer biomarker market: the lack of extensive reimbursement policies for biomarker tests in both emerging and developed countries. This gap in coverage limits the widespread adoption of these essential diagnostic tools, thereby restraining the global demand for biomarkers. Moreover, the high costs associated with cancer diagnosis and treatment, which are particularly burdensome in emerging economies, pose a significant obstacle. These financial constraints further impede the accessibility and use of advanced biomarkers, affecting their market growth and adoption.

Market Trends of the Global Cancer Biomarkers Market

The cancer biomarkers market is set for substantial growth over the next decade, driven by several key factors. A major catalyst is the increasing awareness among patients and healthcare professionals about the crucial role early detection plays in managing cancer. This growing understanding promotes a proactive approach to diagnosis, leading to earlier interventions that can significantly enhance treatment effectiveness. This shift towards early detection is expected to stimulate demand for cancer biomarkers, as timely identification of malignancies can lead to better outcomes and more effective treatments. As awareness continues to rise, the market for these diagnostic tools is likely to expand, reflecting the critical need for advancements in cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Pricing Analysis
• Patent Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Trade Analysis
• Technology Analysis
• Customer & Buying Criteria Analysis
• Case Study Analysis

Cancer Biomarkers Market by Profiling Technology

• Market Overview
• Omics Technologies
  • Proteomics
  • Immunoassays
  • Mass Spectrometry
  • 2D Gel Electrophoresis
  • Protein Microarrays
  • Other Proteomic Technologies
  • Genomics
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • In Situ Hybridization
  • Other Omics Technologies
• Imaging Technologies
  • Ultrasound Imaging
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Mammography

Cancer Biomarkers Market by Cancer Type

• Non-Hodgkin'S Lymphoma
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Non-Hodgkin's Lymphoma
• Kidney Cancer
• Other Cancers

Cancer Biomarkers Market by Product

• Market Overview
• Instruments
  • Imaging Instruments
  • Pathology-Based Instruments
  • Biopsy Instruments
• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
• Bioinformatics Software

Cancer Biomarkers Market by Application

• Market Overview
• Diagnostics
• Research & Development
• Prognostics
• Risk Assessment
• Other Applications

Cancer Biomarkers Market by End User

• Market Overview
• Diagnostic Laboratories
• Biopharmaceutical Companies And Cros
• Research And Academic Institutes
• Other End Users

Cancer Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centogene N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems, Inc. (US, part of Bio-Techne)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovision Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olink (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meso Scale Diagnostics, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invivoscribe, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INOVIQ Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments